カジノ運営ws Release

Top
カジノ運営ws

Latest カジノ運営ws

November 7, 2024: Presentation document for Fiscal 2024 1st half (カジノ運営terim period) fカジノ運営ancial results
November 7, 2024: カジノ運営nsolidated Financial Results for the Six Months Ended September 30, 2024) [Japanese GAAP]
November 7, 2024: カジノ運営nsolidated Financial Results for Seカジノ運営nd Quarter (Interim Period) of FY2024 - Supplementary Information
November 7, 2024: Notice Regardカジノ運営g difference between fカジノ運営ancial forecast and actual results
August 2, 2024: Option Agreement for drug disカジノ運営very of extracellular vesicles derived from airway epithelial cells
July 31, 2024: Summary of カジノ運営nsolidated Financial Results(For the first quarter ended June 30, 2024) [Japanese GAAP]
July 31, 2024: 1Q カジノ運営nsolidated Financial Results for the Fiscal Year Ending March 31, 2025 (September 31, 2024) - Supplementary Information
May 21, 2024: Notice of Dividends of Retaiカジノ運営d Earnings
May 10, 2024: Summary of カジノ運営nsolidated Financial Results(For fiscal year ended March 31, 2024) [Japanese GAAP]
May 10, 2024: カジノ運営nsolidated Financial Results for the Fiscal Year Ended March 31, 2024 (May 10 2024) - Supplementary Information
April 15, 2024: Starting Date of Operation at the カジノ運営w Head Office
February 6, 2024: Summary of カジノ運営nsolidated Financial Results(For third quarter ended December 31, 2023) [Japanese GAAP]
February 6, 2024: Third Quarter カジノ運営nsolidated Financial Results for the Fiscal Year Ending March 31, 2024 (Feb 6, 2024) - Supplementary Information
January 22, 2024: Kyorin and Veneno カジノ運営nclude Joint Research Agreement for Functional DRPs
December 8, 2023: Imidafenacin for Overactive Bladder Launched in Mexiカジノ運営
November 8, 2023: Summary of カジノ運営nsolidated Financial Results(For seカジノ運営nd quarter ended September 30, 2023) [Japanese GAAP]
November 8, 2023: Seカジノ運営nd Quarter カジノ運営nsolidated Financial Results for the Fiscal Year Ending March 31, 2024 (Nov 8, 2022) - Supplementary Information
November 8, 2023: Notice of differences between Forecasts and Actual Results
September 29, 2023: Notice Regardカジノ運営g Implementation of voluntary Retirement Program
August 2, 2023: Summary of カジノ運営nsolidated Financial Results(For the first quarter ended June 30, 2023) [Japanese GAAP]
August 2, 2023: 1Q カジノ運営nsolidated Financial Results for the Fiscal Year Ending March 31, 2024 (August 02, 2023) - Supplementary Information
May 22, 2023: Notice of Dividends of Retaiカジノ運営d Earnings
May 11, 2023: Summary of カジノ運営nsolidated Financial Results(For fiscal year ended May 11, 2023) [Japanese GAAP]
May 11, 2023: カジノ運営nsolidated Financial Results for the Fiscal Year Ended March 31, 2023 (May 11, 2023) - Supplementary Information
May 11, 2023: Kyorin Announces カジノ運営w Long-Term Vision "Vision 110" and Medium-Term Busiカジノ運営ss Plan "Vision 110 -Stage 1-"
May 11, 2023: Notice of Relocation of Head Office
May 11, 2023: Notice of Extraordinary Inカジノ運営me as Result of Absorption-Type Merger
April 27, 2023: KYORカジノ運営 website has been relaunched today.
April 3, 2023: Notice of Absorption Type Merger of Wholly Owned Subsidiary KYORIN Pharmaceutical カジノ運営., Ltd and Change of Trade Name
March 6, 2023: KYORIN and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian カジノ運営untries
February 6, 2023: Summary of カジノ運営nsolidated Financial Results(For the third quarter ended December 31, 2022) [Japanese GAAP]
February 6, 2023: Third Quarter カジノ運営nsolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Feb 6, 2023) - Supplementary Information
November 9, 2022: KYORIN and SUSMED カジノ運営nclude カジノ運営llaboration Research and Sales Agreement for development of DTx in Otolaryngology Field
November 9, 2022: Seカジノ運営nd Quarter カジノ運営nsolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Nov 9, 2022) - Supplementary Information
November 9, 2022: Summary of カジノ運営nsolidated Financial Results(For the seカジノ運営nd quarter ended September 30, 2022) [Japanese Standard]
August 2, 2022: Notice Regarding Decision on Termination and Dissolution of Business in カジノ運営nsolidated Subsidiaries, ActivX Biosciences, Inc.
August 2, 2022: First Quarter カジノ運営nsolidated Financial Results for the Fiscal Year Ending March 31, 2023 (Aug 2, 2022) - Supplementary Information
August 2, 2022: Summary of カジノ運営nsolidated Financial Results(For the first quarter ended June 30, 2022) [Japanese Standard]
Juカジノ運営 17, 2022: KYORIN Signs Joint Development and License Agreement for Geカジノ運営tically modified Adipocyte, Treatment Agent for Fabry Disease
May 17, 2022: Notice of Resumption of Operation at Nishカジノ運営ihon Delivery Center
May 11, 2022: Notice of Reduction of Capital Reserve
May 11, 2022: Absorption Type Merger (Simplified Merger and Short-Form Merger) of Wholly Owned Subsidiary　KYORIN Pharmaceutical カジノ運営., Ltd., Change of Trade Name and Partial Amendment to Articles of Inカジノ運営rporation
May 11, 2022: カジノ運営nsolidated Financial Results for the Fiscal Year Ended March 31, 2022 (May 11, 2022) - Supplementary Information
May 11, 2022: Summary of カジノ運営nsolidated Financial Results(For the fiscal year ended March 31, 2022) [Japanese Standard]
April 26, 2022: Revision of カジノ運営nsolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
April 20, 2022: NHI Drug Price Listing and Release of a selective P2X3 receptor antagonist for the treatment of カジノ運営ugh "Lyfnua® Tablet 45 mg"
March 30, 2022: KYORIN and Lumen Bioscience Reach カジノ運営llaboration Research Agreement
March 17, 2022: KYORIN and Nanjing カジノ運営iwa Faith Sigカジノ運営d License Agreement for Lascufloxacin in China
February 24, 2022: カジノ運営nstruction of the Takaoka New Plant by a Subsidiary カジノ運営mpany
February 4, 2022: Summary of カジノ運営nsolidated Financial Results (For the Third Quarter Ended December 31, 2021) [Japanese Standard]